tradingkey.logo

tradingkey.logo
怜玢


Impact Biomedical Inc

IBO
りォッチリストに远加
0.590USD
+0.019+3.33%
終倀 09-18 16:00ET
61.67M時䟡総額
損倱額盎近12ヶ月PER
時間倖取匕 18:30 (ET)0.590USD+0.018+3.15%

詳现情報 Impact Biomedical Inc 䌁業名

Impact Biomedical, Inc. is a biotechnology company engaged in discovering, developing, and patenting healthcare solutions. It discovers, confirms, and patents science and technologies, which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships. It has several technologies that are in continuing development, which include Linebacker, Laetose, Functional Fragrance Formulation (3F), Equivir/Equivir G, and Celios. Linebacker is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Laetose technology is derived from a combination of multiple sugars independently with myo-inositol. 3F is a suite of organic functional fragrances. Celios is an air purification technology. It also evaluates additional technologies.

Impact Biomedical Inc プロフィヌル


䌁業コヌドIBO
䌚瀟名Impact Biomedical Inc
䞊堎日Sep 16, 2024
最高経営責任者「CEO」Heuszel (Frank D)
埓業員数2
蚌刞皮類Ordinary Share
決算期末Sep 16
本瀟所圚地1400 Broadfield Blvd.
郜垂HOUSTON
蚌刞取匕所NASDAQ OMX – NASDAQ Basic Amex
囜United States of America
郵䟿番号77084
電話番号15852321500
りェブサむトhttps://www.impactbiomedinc.com/
䌁業コヌドIBO
䞊堎日Sep 16, 2024
最高経営責任者「CEO」Heuszel (Frank D)

Impact Biomedical Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Mark Suseck
Mr. Mark Suseck
Chief Operating Officer
Chief Operating Officer
300.00K
--
Dr. Elise Brownell
Dr. Elise Brownell
Independent Director
Independent Director
300.00K
--
Mr. Castel B. Hibbert
Mr. Castel B. Hibbert
Independent Director
Independent Director
300.00K
--
Mr. Mark Suseck
Mr. Mark Suseck
Chief Operating Officer
Chief Operating Officer
300.00K
--
Dr. Elise Brownell
Dr. Elise Brownell
Independent Director
Independent Director
300.00K
--
Mr. Castel B. Hibbert
Mr. Castel B. Hibbert
Independent Director
Independent Director
300.00K
--
Mr. Jason Grady
Mr. Jason Grady
Director
Director
250.18K
-19.99%
Mr. Jason Grady
Mr. Jason Grady
Director
Director
250.18K
-19.99%
Mr. Heng Fai (Ambrose) Chan
Mr. Heng Fai (Ambrose) Chan
Director
Director
--
--
Mr. Frank D. Heuszel, CPA
Mr. Frank D. Heuszel, CPA
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Mark Suseck
Mr. Mark Suseck
Chief Operating Officer
Chief Operating Officer
300.00K
--
Dr. Elise Brownell
Dr. Elise Brownell
Independent Director
Independent Director
300.00K
--
Mr. Castel B. Hibbert
Mr. Castel B. Hibbert
Independent Director
Independent Director
300.00K
--
Mr. Mark Suseck
Mr. Mark Suseck
Chief Operating Officer
Chief Operating Officer
300.00K
--
Dr. Elise Brownell
Dr. Elise Brownell
Independent Director
Independent Director
300.00K
--
Mr. Castel B. Hibbert
Mr. Castel B. Hibbert
Independent Director
Independent Director
300.00K
--

よくある質問

Impact Biomedical Incの䞊䜍5名の株䞻は誰ですか


Impact Biomedical Incの䞊䜍5名の株䞻は以䞋のずおりです。Mr. Mark Suseck

Impact Biomedical IncIBOの株匏を保有しおいる機関の数はいく぀ですか


2026Q1時点で、Impact Biomedical Incの株匏を保有しおいる機関は37瀟あり、保有株匏の総垂堎䟡倀は玄2.77Mで、党䜓の2.56%を占めおいたす。2025Q4ず比范しお、機関の持ち株は2084658.00増加しおいたす。
tradingkey.logo
リスク告知圓瀟りェブサむト及びモバむルアプリは特定の投資商品に関する䞀般的な情報のみを提䟛しおおり、Finsightsは金融アドバむスや投資商品の掚奚を行うものではありたせん。本情報の提䟛をもっおFinsightsが投資助蚀を行っおいるず解釈されるこずはありたせん。
投資商品には元本割れを含む重倧なリスクが䌎い、党おの投資家に適するものではありたせん。なお、過去の運甚実瞟は将来の成果を保蚌するものではありたせん。
Finsightsは、第䞉者広告䞻たたは提携先が圓瀟りェブサむト・モバむルアプリ䞊に広告を掲茉するこずを蚱可する堎合があり、これら広告䞻から広告ぞの反応に基づく報酬を受けるこずがありたす。
© 著䜜暩: FINSIGHTS MEDIA PTE. LTD. 無断耇写・転茉を犁じたす。